Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Medical | 2 | 2024 | 287 | 1.170 |
Why?
|
| Students, Medical | 2 | 2024 | 350 | 1.100 |
Why?
|
| Biological Therapy | 1 | 2021 | 26 | 0.670 |
Why?
|
| Drug Labeling | 1 | 2020 | 29 | 0.630 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 94 | 0.610 |
Why?
|
| Antimicrobial Stewardship | 1 | 2020 | 88 | 0.580 |
Why?
|
| Bacterial Infections | 1 | 2020 | 326 | 0.510 |
Why?
|
| Ambulatory Care | 1 | 2020 | 407 | 0.500 |
Why?
|
| Mass Screening | 1 | 2021 | 825 | 0.440 |
Why?
|
| Mannans | 1 | 2014 | 14 | 0.430 |
Why?
|
| beta-Glucans | 1 | 2014 | 21 | 0.420 |
Why?
|
| Lung Diseases, Fungal | 1 | 2014 | 37 | 0.420 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2014 | 155 | 0.410 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 777 | 0.410 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 2578 | 0.350 |
Why?
|
| Professional Misconduct | 1 | 2024 | 34 | 0.210 |
Why?
|
| Faculty | 1 | 2024 | 98 | 0.190 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2021 | 9 | 0.170 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 82 | 0.160 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2021 | 51 | 0.160 |
Why?
|
| Learning | 1 | 2024 | 374 | 0.160 |
Why?
|
| Bronchitis | 1 | 2020 | 33 | 0.160 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 26 | 0.160 |
Why?
|
| Drug Utilization | 1 | 2020 | 164 | 0.150 |
Why?
|
| Sinusitis | 1 | 2020 | 116 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 230 | 0.140 |
Why?
|
| Gliotoxin | 1 | 2017 | 1 | 0.140 |
Why?
|
| Aspergillus | 1 | 2017 | 26 | 0.130 |
Why?
|
| Aspergillosis | 1 | 2017 | 46 | 0.130 |
Why?
|
| STAT1 Transcription Factor | 1 | 2017 | 75 | 0.130 |
Why?
|
| Ubiquitin | 1 | 2017 | 133 | 0.130 |
Why?
|
| Gain of Function Mutation | 1 | 2017 | 116 | 0.130 |
Why?
|
| Curriculum | 1 | 2021 | 785 | 0.120 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2015 | 43 | 0.120 |
Why?
|
| Central Nervous System Infections | 1 | 2015 | 20 | 0.120 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 331 | 0.120 |
Why?
|
| Neutrophil Infiltration | 1 | 2015 | 65 | 0.120 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 260 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2020 | 1224 | 0.110 |
Why?
|
| Candidiasis | 1 | 2015 | 132 | 0.110 |
Why?
|
| Scopulariopsis | 1 | 2014 | 1 | 0.110 |
Why?
|
| Paecilomyces | 1 | 2014 | 4 | 0.110 |
Why?
|
| Fusariosis | 1 | 2014 | 5 | 0.110 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2014 | 5 | 0.110 |
Why?
|
| Galactose | 1 | 2014 | 53 | 0.110 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2014 | 34 | 0.100 |
Why?
|
| Mucormycosis | 1 | 2014 | 31 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2015 | 212 | 0.100 |
Why?
|
| Humans | 8 | 2024 | 131967 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 3708 | 0.080 |
Why?
|
| Time Factors | 1 | 2020 | 6285 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2020 | 17703 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2148 | 0.070 |
Why?
|
| Risk Factors | 2 | 2020 | 10998 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2992 | 0.060 |
Why?
|
| United States | 1 | 2020 | 11827 | 0.050 |
Why?
|
| Mutation | 1 | 2017 | 6200 | 0.050 |
Why?
|
| Americas | 1 | 2021 | 52 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2017 | 3864 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2021 | 772 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2021 | 466 | 0.030 |
Why?
|
| Candidiasis, Chronic Mucocutaneous | 1 | 2017 | 5 | 0.030 |
Why?
|
| SUMO-1 Protein | 1 | 2017 | 8 | 0.030 |
Why?
|
| Pulmonary Aspergillosis | 1 | 2017 | 9 | 0.030 |
Why?
|
| COS Cells | 1 | 2017 | 249 | 0.030 |
Why?
|
| Sumoylation | 1 | 2017 | 41 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 1252 | 0.030 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2017 | 70 | 0.030 |
Why?
|
| Steroids | 1 | 2017 | 172 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 205 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 417 | 0.030 |
Why?
|
| Transfection | 1 | 2017 | 960 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2021 | 767 | 0.030 |
Why?
|
| Female | 3 | 2021 | 71316 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1572 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 904 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 1018 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 772 | 0.030 |
Why?
|
| Liver | 1 | 2021 | 1802 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 1503 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 392 | 0.020 |
Why?
|
| Male | 2 | 2021 | 65357 | 0.020 |
Why?
|
| Cell Line | 1 | 2017 | 2607 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 1398 | 0.020 |
Why?
|
| Animals | 3 | 2017 | 34460 | 0.020 |
Why?
|
| Biomarkers | 1 | 2021 | 3415 | 0.020 |
Why?
|
| Mice | 2 | 2017 | 18504 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4684 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 10108 | 0.020 |
Why?
|
| Adolescent | 1 | 2021 | 21008 | 0.010 |
Why?
|
| Adult | 1 | 2021 | 31734 | 0.010 |
Why?
|